On Jan 23, 2020, Suzhou Zelgen Biopharmaceuticals Co., Ltd (“Zelgen”, or the “Company”, 688266.SH) successfully listed on SSE STAR Market. CICC acted as Sole Sponsor and Lead Underwriter for the offering. Zelgen is the first company with no revenue and profit generated and the first company listing on the STAR Market applying the 5th set of listing standards on the history of A-share market. 

Zelgen’s listing on the STAR Market as the first company applying the 5th set of listing standards not only shows the inclusiveness of the STAR MARKET and the achievement of China’s capital market reform, but also plays a demonstrative role for many innovative Bio-companies.

As the leading innovation-driven enterprise specializing in the R&D of chemical and biological drugs in the areas of oncology, hematology and gastroenterology, Zelgen is committed to developing and producing innovative drugs that are safe, effective, affordable and have intellectual property ownership to meet the huge clinical needs at home and abroad. Zelgen has successfully established two cutting-edge technology platforms, i.e. the R&D and commercializing platforms for the discovery and development of small molecule and recombinant protein drugs. The Company has also built up diversified pipelines covering different stages of drug research and development, and most products in the pipelines have potential to treat multiple diseases. As of December 9, 2019, the Company had 29 projects for 11 major drugs under development, including 4 in Phase II / III, 2 in Phase I, 1 in IND, and 4 in preclinical R&D. Donafenib, one of the core products, is the first domestic new target drug which completed the phase III clinical trial as first line treatment for advanced hepatocellular carcinoma in China. All the Company's products are in the R&D stage currently, and have not been commercialized to generate any sales revenue. 

As the Sole Sponsor and Lead Underwriter, CICC closely followed the execution throughout the whole course of the transaction. With professional and efficient deal execution and team collaboration, CICC assisted the Company in listing on the SSE STAR Market as the first company with no revenue and profit generated. CICC provided high-quality and comprehensive investment banking services and assisted the Company in regulatory communications to overcome multiple difficulties in review and approval process and facilitate the deal to proceed smoothly. CICC deeply tapped into the investment highlights and warmed up the deal through multiple rounds of marketing to lay a solid foundation for the successful issuance. CICC received high recognition from the Company by providing first-class service. 

As a leading Investment Bank with “China Roots, International Reach” and “People-Oriented, Country-Oriented”, CICC will continue to utilize capital market expertise and rich experience and provide customers with first-class and high quality financial services to achieve strategic development goals.